EyePoint Pharmaceuticals Downgraded After Mixed DURAVYU Phase 3 Trial Results

Key Facts

1RBC Capital downgraded EyePoint Pharmaceuticals to Sector Perform after its Phase 3 LUGANO trial for DURAVYU missed its primary endpoint.

2The company's stock plummeted 66.98% to a 52-week low of $3.95 following the clinical data release.

3A separate analysis excluding a small patient subgroup showed DURAVYU performed as well as the current standard treatment, aflibercept.

Amid heightened volatility in the biotech sector, EyePoint Pharmaceuticals faced intense selling pressure following clinical setbacks. RBC Capital downgraded the company to 'Sector Perform' after its Phase 3 LUGANO trial for DURAVYU, a treatment for wet age-related macular degeneration (wet AMD), missed its primary endpoint. According to reports, the failure was attributed to vision loss in a small 4% subgroup of participants due to causes unrelated to the condition, which overshadowed the study's broader data.

Despite missing the primary goal, separate analyses revealed silver linings; DURAVYU performed as well as the standard treatment, aflibercept, when excluding the affected subgroup and demonstrated a 42% reduction in treatment burden. However, competitive pressure mounted as peer company REGENXBIO announced positive trial data for its own treatment. Per analyst facts, EyePoint's stock plummeted 66.98% to a 52-week low of $3.95 following the release of the mixed clinical results.

Investors are now watching for EyePoint's ability to restore confidence in its clinical pipeline following this significant correction. As of August 18, 2026, updated instrument prices are unavailable in the database, meaning price action remains driven by market reaction to the trial data. With no immediate sector-specific catalysts in the upcoming economic calendar, focus remains on internal company developments and subsequent analyst revisions.

Sources:

Financial Modeling Prep